KR20200083140A - Compositions comprising extracts of Sophorae fructus and Paeonia lactiflora for preventing or improving menopausal symptoms - Google Patents

Abstract

The present invention relates to a food composition for preventing or alleviating a menopausal symptom and a pharmacological composition for preventing or treating a menopausal symptom including extracts of fruits of Styphnolobium japonicum and Paeonia japonica as an active ingredient, and more specifically, to a composition for preventing, alleviating, or treating a menopausal symptom which is caused by a decrease of estrogen in a body by coadministering extracts of fruits of Styphnolobium japonicum and Paeonia japonica. The composition according to the present invention provides an excellent effect and a reduced side effect due to synergism of estrogen-like activity of the fruits of Styphnolobium japonicum and the Paeonia japonica, and alleviates or reduces a female climacteric or menopausal symptom.

Description

Compositions comprising extracts of Sophorae fructus and Paeonia lactiflora for preventing or improving menopausal symptoms}

This application claims priority to Korean Patent Application No. 10-2018-0174012 filed on December 31, 2018, the entire specification of which is incorporated herein by reference.

The present invention relates to a composition for preventing or ameliorating or treating menopausal symptoms of female menopausal symptoms comprising an active ingredient of an extract of whiteberry fruit and an extract of whitewood, and more specifically, synergistic effect of the combined administration of an extract of whiteberry fruit and an extract of whiteberry It relates to a food composition and a pharmaceutical composition for preventing or improving menopausal symptoms caused by reduction of estrogen in the body by using.

Women experience endocrine metastasis before and after menopause, when menstruation is permanently stopped, and even after menopause, women experience a variety of mental and physical symptoms and discomfort caused by lack of female hormones. It is diagnosed as menopause one year after the period is over, and the period before and after menopause progresses is called menopause. The period from menstrual irregularities to menopause before menopause is called menopausal transition period, that is, when women transition from fertility to menopause. In Korea, despite the tendency of menarche age to decrease, menopausal age was found to be on average between 51 and 55 years old. As the proportion of women among Koreans and the proportion of middle-aged women are increasing, and the proportion of middle-aged women's participation in and participation in economic activities is also large, all kinds of menopause symptoms of all middle-aged women are relieved to reduce mental and physical health. In addition, it is very important to seek ways to improve the quality of life.

Unlike men, the reason women experience major endocrine disruption and related symptoms before and after menopause is determined by the number of follicles that are the main source of female hormones since birth, and new follicles are then created to compensate for follicles that are lost during menstruation. Because it is not. After about 40 years of fertility, about 480 oocytes mature and are discharged, and the rest degenerate and disappear, so postmenopausal women are in severe female hormone deficiency. Estrogen, a representative female hormone, is secreted mainly from the follicle and luteum of the ovaries, and plays an important role in regulating the menstrual cycle through the expression of sexual characteristics such as the development of the female genital organs and the breast and endometrial regulation. In addition, since estrogen deficiency affects various organs and symptoms in various organs, as it affects various body functions, such as maintenance of blood vessels and skin, suppression of bone absorption and bone formation, improvement of platelet coagulation, fat breakdown, and body fluid balance, etc. Is expressed as Facial flushing, the earliest and most common symptom experienced during menopause, is caused by abnormal control of vascular movement, and sudden burning and sensation in the neck and chest. In addition, tachycardia and sweating may be caused by vascular problems. In addition, epithelial abnormalities such as vaginal dryness, vaginal atrophy, urinary incontinence, urinary tract infection, urinary urgency, and urinary frequency appear, in which the epithelial cell thickness of the vagina and urethra decreases, the mucous membranes contract and lose elasticity. Estrogen deficiency also affects the central nervous system, which can lead to impaired cognitive function, and may also lead to urogenital abnormalities such as insomnia (sleep disorder), anxiety, anxiety, anxiety, depression, memory loss, libido, lethargy. . In the long term after menopause, chronic musculoskeletal disorders such as osteoporosis and joint pain are of concern. Female hormones are important for maintaining bone density, and when female hormones decrease during menopause, calcium is released from the bones, thereby reducing bone density and deforming bone microstructure, leading to osteoporosis, which weakens the bone quality of the femur and iliac bone. In addition, hypertension and coronary artery disease may occur due to an increase in cholesterol in the blood, and a decrease in basic metabolism may lead to abdominal obesity.

Hormone replacement therapy is typically used to treat these menopausal symptoms. It is a method of supplementing female hormones that are not sufficiently produced in the body due to menopause. Hormonal therapy improves various symptoms caused by hormone deficiency, especially osteoporosis and heart disease, by restoring reduced estrogen levels to normal. However, when receiving hormone replacement therapy for a long period of time, the risk of developing female cancer such as breast cancer or endometrial cancer increases, and there is a disadvantage that all menopausal women or all menopausal symptoms cannot be alleviated. In particular, side effects such as vaginal bleeding, nausea, vomiting, breast pain, and bloating are not uncommon. Accordingly, it is necessary to find alternative therapies that can restore the function of estrogen deficient in postmenopausal women with less toxicity and side effects, and to discover substances with estrogen-like activity.

Accordingly, the present inventors have researched to find a combination capable of optimizing the effect of natural substances having a relieving effect of menopausal or menopausal symptoms. This was observed. Accordingly, the present invention was completed by confirming that the composite composition comprising the extract of prickly berry fruit and the extract of medicinal pear can effectively improve the symptoms of climacteric or menopausal women caused by a decrease in estrogen secretion in the body.

Accordingly, an object of the present invention is to provide a composition for the prevention or improvement of menopausal symptoms in women, which includes the extract of prickly pear fruit and the extract of pea medicinal as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of menopausal symptoms of women, which includes as an active ingredient an extract of prickly pear fruit and an extract of rooster.

In order to achieve the above object, the present invention provides a composition for preventing or improving symptoms of menopausal symptoms in women, which includes as an active ingredient an extract of prickly pear fruit and an extract of rooster.

In order to achieve another object of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of menopausal symptoms in women, which includes as an active ingredient an extract of prickly pear fruit and an extract of peach.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for preventing or improving symptoms of menopausal symptoms in women, which includes the extract of prickly pear fruit and the extract of pea medicinal as an active ingredient.

In the present specification, “menopausal symptoms” refers to symptoms caused by hormone deficiency that occurs before and after menopause, before and after menopause, or throughout menopause, and is specifically related to menopause in women. The production and secretion of female hormones, such as estrogen and progestogen, decreases due to natural aging or disease and the function of the ovaries decreases, and the phenomenon that ovulation and menstruation stops is'menopause', and the period before and after menopause progresses. It is called menopause or menopause. Menopause is strictly a comprehensive term rather than menopause, meaning a period of transition from childbearing to menopause.

The "menopausal symptoms" according to the present invention preferably means symptoms characterized by a decrease in estrogen secretion in the body. More specifically, the menopausal symptoms include menstrual disorders, hot flashes, tachycardia, sweating, cognitive impairment, memory impairment, sleep disorders, vaginal dryness, vaginal atrophy, fatigue, depression, osteoporosis, joint pain, alopecia, atherosclerotic cardiovascular disease and hyperlipidemia. Characterized in that one or more selected from the group.

According to the results confirmed by the present inventors through experiments, the extract of prickly pear fruit and the extract of the county pear promote cell proliferation and show estrogen-like activity in MCF-7 cells, which are estrogen-dependent cell lines, respectively. Furthermore, when the coniferous fruit extract and the white medicinal extract are used together, the estrogen-like activity is more improved than when each extract is treated alone. Therefore, it can be seen that the complex extract containing the coniferous tree extract and the extract of the ear of the county can be effectively used to improve the symptoms of menopausal women caused by estrogen reduction.

In this specification, Sophorae fructus is a fruit of Sophora japonica L. belonging to the legume family, and contains 1 to 6 dark brown or black seeds in a bean pod-shaped weft. It has the effect of anti-inflammatory and hemostasis, and harvests ripe fruits from the private or oriental medicine and roasts the dried ones as it is or uses it as a medicine. It can also be used as ginsil, ginja, and gindu. Is called. It tastes slightly bitter and tastes sour. Due to the cold and heat-acting nature, people with weak digestive tracts or weak pulses should not be overdose, and some people may be allergic.

'Peonia lactiflora Pall or Paeonia albiflora ' in the present specification is a perennial plant of the peony family, and is also called a flower in the shape of a flower and has been cultivated for ornamental and medicinal purposes. It has been used as a medicine for pain relief, soothing, and anti-inflammatory in oriental medicine, and is also used for symptoms of digestive disorders that cause abdominal pain and diarrhea. In the present specification, the extract of the count of peony means an extract of the root of the count of peony.

The composition according to the present invention is characterized in that it contains an extract of the extract of the narcissus fruit and the extract of the county medicinal, and preferably comprises the extract of the narcissus fruit and the extract of the county berry in a weight ratio of 1:1 to 1:500. . If the blending ratio is less than 1:1, the combination effect of estrogen activity of the extract of whiteberry fruit extract and the extract of the county may not appear, and if it is 1:500 or more, the economic efficiency may be deteriorated compared to the effect.

The extract is characterized in that it is extracted with one or more solvents selected from the group consisting of water, alcohol, alcohol having 1 to 5 carbon atoms, ethyl acetate, hexane, dichloromethane, acephone, chloroform, methylene chloride, and mixtures thereof. Most preferably it can be extracted using alcohol.

The extract for the composition of the present invention can be extracted by a known natural product extraction method, for example, it can be extracted by a solvent extraction method. Alcohol, acetone, ether, chloroform, ethyl acetate, methylene chloride, hexane, such as water, ethanol, alcohol, methanol, propanol, isopropanol, butanol , Cyclohexane, petroleum ether (petroleum ether), diethyl ether, benzene can be extracted using any one selected from organic solvents or a mixed solvent thereof.

As an extract for the composition of the present invention, the extract extracted by the solvent extraction method may be used as it is, or may be separated, fractionated, purified, or filtered by a known method to remove impurities and increase the concentration of the active ingredient. Solvents for fractionation include alcohols having 1 to 6 carbon atoms such as water, ethanol, alcohol and methanol, ethyl acetate, methylene chloride, dichloromethane, chloroform, n-hexane (n-Hexane), diethyl ether, acetone, and benzene. Any one selected from the same organic solvent or a mixed solvent thereof can be used. Fractions can be used as is or re-fractionated. The final extract may be concentrated by a known method such as azeotropic concentration, concentrated under reduced pressure, and may be prepared in powder form by removing and solidifying the solvent by a method such as freeze drying and spray drying.

In the present embodiment, the painting tree fruit was extracted using 60% alcohol, filtered and concentrated, and then dried and powdered with a spray dryer. Similarly, extracts of other natural products were prepared by hot water extraction or alcohol extraction, and powdered by spraying or freeze drying.

In addition, the composition according to the present invention is one or more selected from the group consisting of red ginseng extract, licorice extract, soybean extract, gamma-linolenic acid, vitamin A, vitamin B6, vitamin C, vitamin D3, and vitamin E known to be helpful for menopausal women. It may further include.

The composition for foods using the extract of prickly pear fruit or peanut according to the present invention includes all forms of functional food, nutritional supplement, health food and food additives. . These types can be prepared in various forms according to conventional methods known in the art.

For example, as a health food, the food composition itself of the present invention may be prepared in the form of tea, juice, and drink to be consumed or granulated, encapsulated, and powdered. In addition, the food composition of the present invention can be prepared in the form of a composition by mixing with a known substance or active ingredient known to have an effect of improving menopausal or menopausal symptoms, such as reducing body fat, improving cholesterol, lowering blood pressure, and the like.

In addition, functional foods include beverages (including alcoholic beverages), fruits and processed foods thereof (eg, canned fruits, canned fruits, jams, marmalades, etc.), fish, meat, and processed foods (eg, ham, Sausage corn beef, etc.), breads and noodles (e.g., udon, buckwheat noodles, ramen, spaghetti, macaroni, etc.), juice, various drinks, cookies, syrup, dairy products (e.g. butter, cheese, etc.), edible plants Oil, margarine, vegetable protein, retort food, frozen food, various seasonings (for example, miso, soy sauce, sauce, etc.) can be prepared by adding the food composition of the present invention.

The preferred content of the food composition according to the present invention is not limited to this, but is preferably 0.01 to 50% by weight of the total weight of the food finally produced. In order to use the food composition of the present invention in the form of a food additive, it may be prepared and used in powder or concentrate form.

In addition, the food composition of the present invention may contain various flavoring agents, natural carbohydrates, and the like, as additional components, like a conventional beverage. The carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatin and stevia extract, synthetic sweeteners such as saccharin and aspartame can be used. The ratio of the natural carbohydrate may be generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention, but is not limited thereto.

The definition of terms for the excipients, binders, disintegrants, glidants, mating agents, flavoring agents, etc. of the present invention are those described in the literature known in the art and include those having the same or similar functions (Korean Pharmacopoeia Commentary, Statement) Seongsa, Korean Council of Pharmacy, 5th edition, p33-48, 1989).

The present invention provides a pharmaceutical composition for the prevention or treatment of menopausal symptoms of females, including the extract of prickly pear fruit and the extract of medicinal peach.

The synergistic effect of estrogen-like activity by concomitant treatment of the extract of Japanese oleander fruit and the extract of Peony is as described above. It can be developed as a medicine that can safely or effectively and economically prevent or treat menopausal symptoms by using a complex composition comprising a coniferous tree extract and a countenance extract. The extraction method and the blending ratio of the extract of the pine tree fruit extract and the extract of the ear of the county contained in the complex extract are as described above.

The pharmaceutical composition according to the present invention may contain a composite composition of the extract of prickly pear fruit extract and the countenance extract alone or may be formulated in a suitable form with a pharmaceutically acceptable carrier, and may additionally contain excipients or diluents. . As used herein,'pharmaceutically acceptable' refers to a non-toxic composition that is physiologically acceptable and does not generally cause an allergic reaction or similar reaction, such as gastrointestinal disorders, dizziness, and the like.

Pharmaceutically acceptable carriers may further include, for example, carriers for oral administration or carriers for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, it may include various drug delivery materials used for oral administration to the peptide preparation. In addition, the carrier for parenteral administration may include water, a suitable oil, saline, aqueous glucose and glycol, and the like, and may further include a stabilizer and a preservative. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-parabens and chlorobutanol. The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifying agent, a suspending agent, etc. in addition to the above components. Other pharmaceutically acceptable carriers and formulations can be referenced as described in the following documents (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).

The composition of the present invention can be administered in any way to mammals, including humans. For example, it can be administered orally or parenterally. The parenteral administration method is not limited to this, but intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal administration. Can be

The pharmaceutical composition of the present invention may be formulated as a formulation for oral administration or parenteral administration according to the administration route as described above.

In the case of preparations for oral administration, the compositions of the present invention may be formulated using methods known in the art as powders, granules, tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, etc. Can. For example, oral preparations can obtain tablets or dragees by blending the active ingredient with a solid excipient and then grinding it and adding a suitable adjuvant to the granule mixture. Examples of suitable excipients are sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch and potato starch, cellulose, etc. Fillers such as cellulose, gelatin, polyvinylpyrrolidone and the like may be included, including methyl cellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose. In addition, if necessary, cross-linked polyvinylpyrrolidone, agar, alginic acid or sodium alginate may be added as a disintegrant. Furthermore, the pharmaceutical composition of the present invention may further include an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and a preservative.

For formulations for parenteral administration, injections, creams, lotions, external ointments, oils, moisturizers, gels, aerosols and nasal inhalants can be formulated by methods known in the art. These formulations are described in Remington's Pharmaceutical Science, 19th ed., Mack Publishing Company, Easton, PA, 1995, a prescription generally known to all pharmaceutical chemistries.

The total effective amount of the composition of the present invention can be administered to a patient in a single dose, and can be administered by a fractionated treatment protocol that is administered for a long time in multiple doses. The pharmaceutical composition of the present invention can vary the content of the active ingredient according to the degree of disease. Preferably, the preferred total dose of the pharmaceutical composition of the present invention may be from about 0.01 μg to 10,000 mg per kg of patient body weight per day, most preferably from 0.1 μg to 500 mg per day. However, the dosage of the pharmaceutical composition is determined by considering various factors such as the formulation method, the route of administration and the number of treatments, as well as the patient's age, weight, health status, sex, disease severity, diet and excretion rate, etc. Considering this, one of ordinary skill in the art will be able to determine an appropriate effective dosage of the composition of the present invention. The pharmaceutical composition according to the present invention is not particularly limited in its formulation, route of administration and method of administration as long as it shows the effects of the present invention.

Therefore, the present invention provides a composition for preventing or improving symptoms of menopausal symptoms in women, including the active ingredient of the extract of the pine tree fruit extract and the ear of the county. The composition according to the present invention can have a similar effect in a smaller amount than the single extract due to the synergistic effect of the estrogen-like activity of the extract of whiteberry fruit and the extract of the county tree, and it is possible to avoid the side effects that may appear in overdose of the extract alone. You can safely and safely improve your menopausal or menopausal symptoms.

Figure 1 shows the MCF-7 cell line proliferation promoting effect of natural extracts at various concentrations. In Figure 1 A is a coniferous fruit extract, B is a county medicinal extract, C is a phosphorus wormwood extract, D is a baekbokryeong extract. The vertical axis represents cell viability (%), and the horizontal axis represents the concentration of each extract (ug/ml).
Figure 2 shows the results of the E-screen experiment for confirming the combined effect of the natural extract and the pine tree extract. The vertical axis represents the relative estrogen-like activity (%) compared on the basis of estradiol, and the horizontal axis represents the natural extract (Peanut medicinal, Insugum wormwood, licorice, Baekbok-ryeong) that compares the effect of concomitant use with the extract of prickly pear fruit. Gray extract group of natural extracts alone (17㎍/mL), white extract group of solanum fruit extract alone (17㎍/mL), black extract group of solanum fruit extract and natural extracts (each 8.5㎍/mL, weight ratio) 1:1 mixture).
Figure 3 shows the results of the E-screen experiment to confirm the effect of the combination ratio of the extract of white pine tree fruit extract and the countenance. The vertical axis represents the relative estrogen-like activity (%) compared to estradiol, and the horizontal axis represents the weight ratio of the extract of prickly pear fruit extract and the count of medicinal extract.

Hereinafter, the present invention will be described in detail.

However, the following examples are only to illustrate the present invention, the content of the present invention is not limited to the following examples.

<Experiment method>

1. Preparation of Extract

The painting wood fruit (Jeseong Pharmaceutical Co., Ltd. in Gyeongdong Market) was washed 20kg, dried and crushed to a size of 30 mesh using a grinder. 60% alcohol was added to the pulverized product, followed by extraction with alcohol, cooled to 50° C., filtered using a 100 mesh filter cloth, and then filtered again with a 200 mesh filter cloth to remove the precipitate and to obtain a filtrate. The supernatant was concentrated to a volume of 1/5 using a concentrator, and then the concentrate was dried and powdered using a spray dryer.

After extracting the hot water by heating the dried peanut powder in purified water corresponding to 5 to 10 times the weight of the sample amount by heating for more than 2 hours at 70°C or more, the extract was filtered with a filter cloth and centrifuged to remove the precipitate. The separated extract was concentrated under reduced pressure and lyophilized.

Other natural product extracts used in this example were also extracted with hot water or spirits in a similar manner.

2. MCF-7 cell line culture and treatment of test substances

Incubated in a humidified CO ₂ incubator at 37℃ and 5% CO ₂ using DMEM medium containing L-glutamine (300mg/ℓ), 25mM NaHCO ₃ , 10% heat inactivated fetal bovine serum (FBS), insulin, etc. Did. Thereafter, cells were dispensed at a concentration of 5x10 ³ cells/ml in a 96 well plate, and then cultured for 24 hours. The test substance was treated and incubated for 20 hours, and after adding MTT solution (final conc. 0.5 mg/ml) for 4 hours, the medium was removed and the cells were lysis using DMSO to degrade the microplate reader. The absorbance was measured at 570 nm to measure cell viability.

3. Estrogen-like activity measurement (E-screen)

Cells were dispensed at a concentration of 2x10 ⁴ cells/ml in a 24 well plate and cultured for 24 hours. 17β-estradiol (E2, 10 ^-13 ~10 ^-8 M) was used as a positive control, and the test substances were treated alone or in combination to further culture for 3 days. MTT solution was added (final conc. 0.5 mg/ml) and further cultured for 4 hours. After removing the medium and lysis of the cells using DMSO, the absorbance was measured at 570 nm using a microplate reader to calculate estrogenic activity compared to E2.

E-screen medium is a phenol red-free medium in which charcoal stripped FBS is added instead of general FBS. It is a medium that excludes all estrogen-like substances and uses estradiol (17β-estradiol) as a standard control. After each treatment for each concentration (10 ^-13 ~10 ^-8 M), the minimum proliferation rate of the standard control was calculated from the cell proliferation rate result for each test substance concentration by calculating the minimum proliferation concentration at which the cell proliferation rate becomes saturated. Estrogen-like activity was confirmed by confirming increase or decrease when the standard was set as %.

<Example 1>

Selection of natural extracts with estrogen-like activity

<1-1> MCF-7 breast cancer cell line growth promoting effect

To find a combination of substances for concomitant administration to maximize the effect of alleviating women's menopausal or menopausal symptoms and minimize side effects, first relieve women's menopausal symptoms or use substances known to be effective in osteoporosis, a typical estrogen deficiency phenomenon. The effect was confirmed by confirming whether or not estrogen-like activity at cell level actually promotes breast cancer cell line proliferation.

As a candidate substance that is known to help women's health or women's menopausal symptoms, natural substances such as prickly pear fruit, cornflower, ginkgo biloba, red ginseng, Angelica, peanut, licorice, pomegranate, soybean, Omija, wormwood, Baekbokryeong, Baeksoo It was selected as a target. And these candidate substances were treated with MCF-7 cell lines at various concentrations (0-20 mg/ml range) alone, and cell viability was measured.

As a result of the experiment, it was found that, unlike the general public, not all candidate substances promoted the proliferation of MCF-7 cells, and differed according to the substances. Some substances were expected to have estrogen-like activity due to the effect of promoting cell proliferation of MCF-7 compared to the negative control without any treatment. However, other substances were similar to the negative control group, or there was no specific effect at certain concentrations, such as the extract of Injingwort and Baekbokryeong, but it was also found that the higher the concentration, the more it inhibited the proliferation of MCF-7 (FIG. 1). In the case of the extract of pea medicinal extract, it was found to be the most effective at 2.5 mg/ml, and in the case of the extract of prickly pear fruit, it showed a remarkable effect in a narrow concentration range near 25 μg/ml.

In addition, it is estimated that, in the case of substances that do not promote the proliferation of MCF-7 cells, it is expected to alleviate menopausal or menopausal symptoms through a mechanism other than estrogen signaling, unlike those previously known to have effects of alleviating menopausal symptoms.

<1-2> Estrogen-like activity confirmation (E-screen)

For the substances known to be helpful for female health or women's menopausal symptom relief screened in <Example 1-1>, it was more directly confirmed whether estrogen-like activity was found in MCF-7 cells. The breast cancer cell line MCF-7 is cultured in a medium without estradiol, the candidate substance is treated with MCF-7 cell line at various concentrations alone, and cell viability is measured to measure estrogen-like activity as known to these candidate substances. I checked if it exists. Since MCF-7 cells are estrogen-dependent cells, in the medium culture conditions lacking estrogen, proliferation is dependent on estrogen-like activity of candidate substances added to the medium.

As a result of the experiment, the activity of the substances to be analyzed showed a similar trend as in <Example 1-1>. That is, unlike known, not all candidate substances exhibited estrogen-like activity in the MCF-7 cell line, and estrogen-like activity exhibited by MCF-7 cell proliferation was found to be different depending on the candidate substance. It has been found that some substances promote the proliferation of MCF-7 cells to a degree similar to that of the positive control, 17β-estradiol, and thus exhibit high estrogen-like activity at the cellular level. On the other hand, other substances had an effect less than that of the positive control group, and the degree of promoting the proliferation of MCF-7 cells was very diverse depending on the substance.

<Example 2>

Estrogen-like activity of natural extracts with combined administration effect

Next, in <Example 1>, it was examined whether a substance identified as having estrogen-like activity was treated together to show synergy of estrogen-like activity (synergy). In <Example 1>, the effect of the combination treatment treated with a combination of two extracts of prickly pear fruit showing estrogen-like activity and other natural extracts was confirmed by the E-screen method of <Example 1-2>.

As a result of the experiments, it was observed that the combined treatment effect of the composite composition of the combination of the extract of prickly pear fruit and other natural extracts appears differently depending on the combined materials. In certain combinations, a higher cell proliferative effect was observed than when each material was treated alone, demonstrating a synergistic effect of estrogen-like activity. However, in other combinations (Inginseng mugwort, Baekbokryeong, licorice, etc.), the effect of the combination treatment was insignificant, or rather, the effect was decreased compared to the treatment with a single substance (Table 1, Figure 2; Table 1 and Figure 2 ' Extract alone' refers to the treatment of natural extracts that are treated in combination with the extract of pine tree fruit).

It was determined that the combination of the Hwaja tree fruit extract and the Count of Pebble extract had a higher effect than the treatment of each extract alone in combination treatment. That is, it was found that when the two extracts were treated together, the effect of promoting the proliferation of MCF-7 cells through estrogen-like activity was further improved than the single extract.

<Example 3>

Determination of compounding ratio for co-administration of estrogen-like active natural substances

In order to determine the mixing ratio of the combination administration of the coniferous fruit extract and the coniferous extract, a composite composition is prepared by mixing the coniferous fruit extract and the coniferous extract in various weight ratios such as 1:1 to 1:256, <Example 1-2> The E-screen method was used to compare the effects of different blending ratios.

The blending ratio and experimental results of the combination treatment of the extract of Coniferous Tree Fruit Extract and the Count of Pebble are as shown in Table 2 and FIG. 3. The combination effect of the extract of oleander fruit extract and the extract of pea medicinal herb did not show a significant difference even though the total amount of treatment increased when the compounding ratio was 1:1 (in contrast to 0.5:0.5 in FIG. 3), the tendency to increase as the compounding ratio increased Looked.

As described above, the present invention provides a pharmaceutical composition for preventing or improving menopausal symptoms, and for preventing or treating menopausal symptoms, including an active ingredient comprising an extract of prickly pear fruit extract and a countenance. The composition according to the present invention can improve female menopausal or menopausal symptoms with excellent effect and reduced side effects due to the synergistic effect of estrogen-like activity of prickly pear fruit and county.

Claims (7)

A composition for the prevention or improvement of menopausal symptoms in women, which includes the extract of Coniferous Tree Fruit and the extract of Peony.
According to claim 1, wherein the composition is a composition characterized in that it comprises a weight ratio of 1: 1 to 1:500 prickly pear fruit extract and white peach extract.
The extract of claim 1, wherein the extract is extracted with one or more solvents selected from the group consisting of water, alcohol, alcohol having 1 to 5 carbon atoms, ethyl acetate, hexane, dichloromethane, acephone, chloroform, methylene chloride, and mixtures thereof. Composition characterized by.
The composition of claim 1, wherein the composition further comprises at least one selected from the group consisting of red ginseng extract, licorice extract, soybean extract, gamma-linolenic acid, vitamin A, vitamin B6, vitamin C, vitamin D3, and vitamin E. Composition to be made.
The composition of claim 1, wherein the menopausal symptoms are due to a decrease in estrogen secretion in the body.
According to claim 1, The menopausal symptoms include menstrual disorders, hot flashes, tachycardia, sweating, cognitive impairment, memory impairment, sleep disorders, vaginal dryness, atrophy, fatigue, depression, osteoporosis, joint pain, alopecia, atherosclerotic cardiovascular disease and A composition characterized in that one or more are selected from the group consisting of hyperlipidemia.
Pharmaceutical composition for the prevention or treatment of menopausal symptoms in women, which includes the extract of Coniferous Tree Fruit and the extract of Peony.

Images